Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. develops late clinical-stage biopharmaceutical programs based on nose-to-brain neurocircuitry and intranasal pherine product candidates. Company news centers on fasedienol nasal spray for the acute treatment of social anxiety disorder, including PALISADE Phase 3 study updates, and refisolone nasal spray for vasomotor symptoms due to menopause.
Recurring updates also cover FDA and IND communications, clinical data from psychiatric and neurological programs, fiscal results, cash-management actions, executive and board changes, and healthcare investor conference presentations. The company’s pipeline is described around investigational intranasal candidates for indications that include social anxiety disorder, major depressive disorder, and menopausal hot flashes.
Vistagen (Nasdaq: VTGN) appointed Angel S. Angelov, MD, MBA, as Chief Medical Officer effective May 18, 2026. He brings over two decades of clinical development and medical affairs experience at firms including Karuna, Neurocrine, Novartis, Teva, and others.
According to Vistagen, the board’s Compensation Committee granted Dr. Angelov an inducement stock option for 150,000 VTGN shares at $0.5955 per share, vesting 25% after one year and the remainder monthly over the following 36 months.
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharma company focused on nose-to-brain pherine-based neuroscience therapies, announced that President and CEO Shawn Singh will join a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 2:35 p.m. ET.
The company will also hold one-on-one investor meetings. A live webcast and replay will be accessible in the Investors section of Vistagen’s website under the “Events” tab.
Vistagen (Nasdaq: VTGN) reported preliminary data from the open-label extension of the Phase 3 PALISADE-3 study of intranasal fasedienol for acute treatment of social anxiety disorder.
In 341 adults using fasedienol as needed for up to 12 months, treatment was well-tolerated with 2.6% discontinuations due to adverse events and none attributed to fasedienol. Over four months, exploratory analyses showed clinically relevant improvements on both the clinician-rated LSAS and patient-reported SPIN, including a 25.4-point mean LSAS improvement at Month 4 and higher responder rates over time.
Vistagen (Nasdaq: VTGN) announced completion of the randomized, double-blind portion of the PALISADE-4 Phase 3 study evaluating fasedienol nasal spray for acute treatment of social anxiety disorder. Topline results from the randomized portion are expected in Q2 2026.
The open-label extension remains ongoing; the company refined the statistical analysis plan to include pre-dose SUDS as a covariate and received no FDA comments on that refinement. The FDA previously granted Fast Track designation for fasedienol in social anxiety disorder.
Vistagen (Nasdaq: VTGN) received an FDA Study May Proceed letter under its IND for refisolone nasal spray, enabling further U.S. Phase 2 development for vasomotor symptoms (hot flashes) due to menopause.
Exploratory Phase 2a (N=36) in Mexico used 3.2 μg intranasal dosing up to five times daily for four weeks, showing an 80% reduction in hot-flash frequency versus 36% for placebo, with effects by week one (p < .001) and no serious drug-related adverse events. Pherin Pharmaceuticals is now a wholly owned subsidiary.
Vistagen (Nasdaq: VTGN) will participate in two investor events in March 2026 focused on neuroscience and CNS investors. The company will hold one-on-one meetings at the Leerink Healthcare Conference in Miami on March 9-11, 2026, and a virtual Stifel CNS fireside chat on March 17, 2026 at 9:00 AM EDT.
The Stifel presentation will be available via live webcast on the company’s Events page and a replay will be posted after the presentation.
Vistagen (Nasdaq: VTGN) will present a corporate overview at the 46th Annual TD Cowen Healthcare Conference on Monday, March 2, 2026 at 3:50 p.m. ET. President and CEO Shawn Singh will deliver the presentation. A replay will be archived on the company’s Investors > Events page at Vistagen.com.
Vistagen (NASDAQ: VTGN) reported fiscal Q3 2026 results and a corporate update emphasizing its PALISADE Program and pipeline progress. The company expects topline randomized results from the PALISADE-4 Phase 3 trial of fasedienol in the first half of 2026. Cash, cash equivalents, and marketable securities totaled $61.8 million as of December 31, 2025.
PALISADE-3 did not meet its primary endpoint, though randomized safety data were favorable. Vistagen named a new CFO and plans an IND submission for refisolone in H1 2026 while continuing cash-preservation measures.
Vistagen (Nasdaq: VTGN) will report fiscal year 2026 third quarter results and hold a corporate update conference call on February 12, 2026 at 2:00 p.m. PT / 5:00 p.m. ET. The event will be webcast live and archived for at least 90 days.
Investors can register for the webcast or pre-register for dial-in access; registrants will receive access details by email.
Vistagen (NASDAQ: VTGN) announced topline results from the PALISADE-3 Phase 3 public speaking challenge study of intranasal fasedienol for acute social anxiety disorder.
The study did not meet its primary endpoint: least squares mean change in SUDS was 13.6 (±1.54 SE) for fasedienol vs 14.0 (±1.51 SE) for placebo, a LS mean difference of 0.4 (p = not significant). There were no treatment differences on secondary endpoints. Safety and tolerability were reported as favorable and consistent with prior trials. Management said it will review results with the FDA, evaluate program impact, and has implemented company-wide cash preservation measures intended to provide runway into 2027.